Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A rare neuroendocrine tumor arising from chromaffin cells of the adrenal medulla (pheochromocytoma) or from sympathetic and parasympathetic ganglia (paraganglioma). These tumors are most often benign and may produce catecholamines in excess causing hypertension and sometimes severe acute cardiovascular complications.
Biomarker and diagnostic research for pheochromocytoma-paraganglioma has been reported in the published literature.
8 clinical trials registered, 3 recruiting. Interventions under study include drug therapy and other interventions. Pipeline includes 4 PHASE2, 1 PHASE1, 1 EARLY_PHASE1. Research is primarily sponsored by academic and government institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT06429397](https://clinicaltrials.gov/study/NCT06429397) |
Data assembled from 4 of 12 sources · Last updated Sep 20, 2026, 5:51 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Anlotinib Combined With Benmelstobart for Advanced Pheochromocytoma
PHASE2 |
Sun Yat-sen University |
NOT_YET_RECRUITING |
[NCT05069220](https://clinicaltrials.gov/study/NCT05069220) | 18F-MFBG PET/CT in the Evaluation of Neural Crest Tumor | EARLY_PHASE1 | Peking Union Medical College Hospital | UNKNOWN |
[NCT03946527](https://clinicaltrials.gov/study/NCT03946527) | LAnreotide in Metastatic Pheochromocytoma / PARAganglioma (LAMPARA) | PHASE2 | Antonio Fojo | ACTIVE_NOT_RECRUITING |
[NCT06427798](https://clinicaltrials.gov/study/NCT06427798) | Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy | PHASE1 | National Cancer Institute (NCI) | RECRUITING |
[NCT03206060](https://clinicaltrials.gov/study/NCT03206060) | Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma | PHASE2 | National Cancer Institute (NCI) | RECRUITING |
102 publications have been identified in PubMed for pheochromocytoma-paraganglioma. Research spans Review / Meta-Analysis (29%), Case Report / Case Series (18%), and Epidemiology / Natural History (16%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 24 | 29% |
Patient case studies | 15 | 18% |
Disease patterns and progression | 13 | 16% |
Laboratory research | 12 | 15% |
Testing and diagnosis research | 7 | 9% |
Clinical study results | 5 | 6% |
New treatment approaches | 5 | 6% |
Other research | 1 | 1% |
Alkaissi H (2026). [PMID: 42113881](https://pubmed.ncbi.nlm.nih.gov/42113881/). *Endocr Relat Cancer*. [Basic Science / Preclinical]
Kwon H (2026). [PMID: 42130021](https://pubmed.ncbi.nlm.nih.gov/42130021/). *Endocrinol Metab (Seoul)*. [Epidemiology / Natural History]
Cole Y (2026). [PMID: 41518596](https://pubmed.ncbi.nlm.nih.gov/41518596/). *J Clin Endocrinol Metab*. [Case Report / Case Series]
Nakamura R (2026). [PMID: 42005593](https://pubmed.ncbi.nlm.nih.gov/42005593/). *IJU Case Rep*. [Case Report / Case Series]
Yao S (2026). [PMID: 41879600](https://pubmed.ncbi.nlm.nih.gov/41879600/). *JACC Case Rep*. [Case Report / Case Series]
Charoenngam N (2026). [PMID: 41685558](https://pubmed.ncbi.nlm.nih.gov/41685558/). *Endocr Relat Cancer*. [Review / Meta-Analysis]
Fuentes-Mendoza JM (2026). [PMID: 41706437](https://pubmed.ncbi.nlm.nih.gov/41706437/). *Expert Rev Cardiovasc Ther*. [Review / Meta-Analysis]
Tabebi M (2026). [PMID: 41597272](https://pubmed.ncbi.nlm.nih.gov/41597272/). *Cells*. [Clinical Trial Publication]
Greenberg SE (2026). [PMID: 42067272](https://pubmed.ncbi.nlm.nih.gov/42067272/). *Endocrinol Metab Clin North Am*. [Review / Meta-Analysis]
Fakı S (2026). [PMID: 41750736](https://pubmed.ncbi.nlm.nih.gov/41750736/). *Diagnostics (Basel)*. [Basic Science / Preclinical]